Hanseatic Management Services Inc Vertex Pharmaceuticals Inc Transaction History

Hanseatic Management Services Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $338 - $362	1 Added 0.06%	1,667 $579,000
Q2 2023 Jul 26, 2023	SELL	$314.42 - $351.91 $4,401 - $4,926	-14 Reduced 0.83%	1,666 $586,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $475,826 - $542,808	1,680 New	1,680 $529,000
Q4 2022 Jan 26, 2023	SELL	$285.76 - $321.48 $6,572 - $7,394	-23 Reduced 1.33%	1,704 $492,000
Q3 2022 Nov 08, 2022	SELL	$273.83 - $305.53 $10,405 - $11,610	-38 Reduced 2.15%	1,727 $500,000
Q2 2022 Aug 05, 2022	BUY	$234.96 - $292.55 $414,704 - $516,350	1,765 New	1,765 $497,000
Q4 2020 Jan 29, 2021	SELL	$207.01 - $276.09 $75,558 - $100,772	-365 Closed	0 $0
Q3 2020 Oct 29, 2020	SELL	$255.65 - $303.1 $660,599 - $783,210	-2,584 Reduced 87.62%	365 $99,000
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $601,580 - $789,194	2,668 Added 949.47%	2,949 $856,000
Q2 2019 Jul 19, 2019	SELL	$164.61 - $190.37 $2,798 - $3,236	-17 Reduced 5.7%	281 $52,000
Q4 2018 Jan 29, 2019	BUY	$151.91 - $192.21 $15,494 - $19,605	102 Added 52.04%	298 $49,000
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $715,922 - $835,013	-4,913 Reduced 96.16%	196 $33,000
Q1 2018 May 02, 2018	BUY	$151.6 - $177.13 $2,577 - $3,011	17 Added 0.33%	5,109 $833,000
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $57,520 - $65,175	419 Added 8.97%	5,092 $763,000
Q3 2017 Nov 07, 2017	SELL	$148.13 - $162.24 $38,661 - $42,344	-261 Reduced 5.29%	4,673 $710,000
Q2 2017 Aug 11, 2017	BUY	N/A	4,934	4,934 $636,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

Stay updated on Hanseatic Management Services Inc with notifications on news.